Winning launches require more than a promising therapy. They demand insight-driven strategic choices, coordination across functions and markets, and the capability to execute and adapt with precision.
More than half of new therapy launches miss their forecast.
Numerous independent studies converge on the same finding. THRIVE’s Launch Success Code™ research across 198 launches dives deep into the drivers and barriers to launch success.
See the research →We work with leading global biopharma companies and innovative biotechs across modalities, from cell and gene therapies to biosimilars. We have experience in all major therapeutic areas and are also rare disease specialists.
Our clients include five of the top 20 global biopharma companies, clinical-stage biotechs preparing a first launch, healthcare services providers, and medical device companies. We also serve venture capital and private equity firms, and large family offices.
Knowing what your competitors don’t about customers, stakeholders, and the competitive field. The foundation of differentiated strategy.
The decisions that determine how a new therapy wins, at launch and long-term. Where to play, how to win, how to configure and execute.
Strategy translated into launch readiness. Pull-through across functions and geographies.
Systems, governance, and playbooks that embed launch excellence into the organization’s DNA, so success does not depend on any one team.
There is no other firm I think of calling prior to calling THRIVE.
If your organization is launching a new therapy where failure is not an option, let's talk.
Start a conversation